BET Proteins and T-Cell Function: Joseph A. Fraietta, PhD

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed his research into the mechanisms of the BET protein family and T cells.

Improving Safety With CAR Engager Proteins

Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.

Cell Therapy for AML Granted Fast Track Designation

A phase 1/2a clinical trial assessing VOR33 is currently enrolling.